Citation Impact
Citing Papers
p53: puzzle and paradigm.
1996 Standout
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
2003 StandoutScience
Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
2010
Loss of cryptochrome reduces cancer risk in p53 mutant mice
2009 StandoutNobel
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Mismatch Repair-dependent Iterative Excision at Irreparable O6-Methylguanine Lesions in Human Nuclear Extracts
2006 StandoutNobel
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
2008
Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature
2008
Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand
2002 Standout
Probing p53 biological functions through the use of genetically engineered mouse models
2005
BRCA1 and BRCA2: 1994 and beyond
2004
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
1997 Standout
Mdm2 promotes the rapid degradation of p53
1997 StandoutNature
Shaping of tumor and drug-resistant genomes by instability and selection
2003
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
2005 StandoutNature
Reconstitution of Human DNA Repair Excision Nuclease in a Highly Defined System
1995 StandoutNobel
TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
2009 Standout
p53 is a NF‐Y‐ and p21‐independent, Sp1‐dependent repressor of cyclin B1 transcription
2005
Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice
2001
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
2006 Standout
p53 polymorphisms: cancer implications
2009
Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
2002
p53 in growth control and neoplasia
1996
Oncogenic kinase signalling
2001 StandoutNature
Reprimo, a New Candidate Mediator of the p53-mediated Cell Cycle Arrest at the G2 Phase
2000
Cell-cycle checkpoints and cancer
2004 StandoutNature
p53, the Cellular Gatekeeper for Growth and Division
1997 Standout
Role of the SCFSkp2 Ubiquitin Ligase in the Degradation of p21Cip1 in S Phase
2003 StandoutNobel
DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2
1997 Standout
ATP-dependent chromatin remodelers in ageing and age-related disorders
2020
P53 and radiation responses
2003
A microRNA component of the p53 tumour suppressor network
2007 StandoutNature
Hallmarks of aging: An expanding universe
2023 Standout
Genetic instabilities in human cancers
1998 StandoutNature
The Protective Effects of Estrogen on the Cardiovascular System
1999 Standout
p21/CDKN1A Mediates Negative Regulation of Transcription by p53
2003
The role of p53 in tumour suppression: lessons from mouse models
1999
Regulation of the G2/M transition by p53
2001 Standout
Stem cells find their niche
2001 StandoutNature
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study
2000
A role for p53 in base excision repair
2001
Immunogenicity of induced pluripotent stem cells
2011 StandoutNature
Blinded by the Light: The Growing Complexity of p53
2009 Standout
Prevalence of the I1307K APC gene variant in Israeli Jews of differing ethnic origin and risk for colorectal cancer
1999
Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors 2 2Abbreviations: CP, cyclophosphamide; PFT, pifithrin-α or p53 inhibitor; HT, hyperthermia; HS, heat shock; HO, hypoxia; and HIF-1, hypoxia inducible factor.
2001
Distinct Sets of Genetic Alterations in Melanoma
2005 Standout
High resolution of human evolutionary trees with polymorphic microsatellites
1994 StandoutNature
Modifiers of risk of hereditary breast and ovarian cancer
2002
Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1
1996
Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a
1997 Standout
Apoptosis
2002 Standout
On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance
2002
Hereditary Colorectal Cancer
2003 Standout
p130/E2F4 Binds to and Represses the cdc2 Promoter in Response to p53
2001
Polymorphisms in the p53 pathway
2006
A model for p53-induced apoptosis
1997 StandoutNature
p53 and Human Cancer: The First Ten Thousand Mutations
1999
Pancreatic Cancer
2010 Standout
p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development
1999 StandoutNature
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes
2007
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA
2003
The multifunctional TFIIH complex and transcriptional control
1994
Transcriptional Repression by p53 through Direct Binding to a Novel DNA Element
2001
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
2009 Standout
Cell cycle control and cancer chemotherapy
1994 StandoutNobel
Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin–Cohort Study in Ontario, Canada
2006
Excision Repair in Mammalian Cells
1995 StandoutNobel
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Cancer of the Ovary
2004 Standout
Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53
2002
Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers
2002
Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers
2002
Regulation of proliferation and differentiation in spermatogonial stem cells: the role of c-kit and its ligand SCF
2000
Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
2011
Ubiquitination of p53 and p21 Is Differentially Affected by Ionizing and UV Radiation
1997
Mechanisms of G2 Arrest in Response to Overexpression of p53
1999
Differential Activation of Target Cellular Promoters by p53 Mutants with Impaired Apoptotic Function
1996
Estrogen-Receptor–Mediated Inhibition of Human Endothelial Cell Apoptosis
1997
The G2 Checkpoint Is Maintained by Redundant Pathways
1999
Cancer Cell Cycles
1996 StandoutScience
Tyrosine Phosphorylation of Transmembrane Ligands for Eph Receptors
1997 StandoutScience
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
2002
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
1998 StandoutScience
Persistence of Tandem Arrays: Implications for Satellite and Simple-Sequence DNAs
1987
Clinical Characteristics of Individuals With Germline Mutations in BRCA1 and BRCA2: Analysis of 10,000 Individuals
2002
Breast Cancer Risk Following Bilateral Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: An International Case-Control Study
2005 Standout
Fallopian Tube and Primary Peritoneal Carcinomas Associated With BRCA Mutations
2003
Surfing the p53 network
2000 StandoutNature
Clinical Characteristics of Individuals With Germline Mutations in BRCA1 and BRCA2: Analysis of 10,000 Individuals
2002
p53 Regulation of G2 Checkpoint Is Retinoblastoma Protein Dependent
2000
The sluggish-A gene of Drosophila melanogaster is expressed in the nervous system and encodes proline oxidase, a mitochondrial enzyme involved in glutamate biosynthesis.
1993
DNA Double-Strand Breaks
2002 StandoutNobel
Genetic susceptibility to non-polyposis colorectal cancer
1999
Sporadic Epithelial Ovarian Cancer: Clinical Relevance of BRCA1 Inhibition in the DNA Damage and Repair Pathway
2008
Abnormal Centrosome Amplification in the Absence of p53
1996 Science
Direct p53 Transcriptional Repression: In Vivo Analysis of CCAAT-Containing G2/M Promoters
2005
hMutSα- and hMutLα-dependent phosphorylation of p53 in response to DNA methylator damage
1999 StandoutNobel
THE UBIQUITIN SYSTEM
1998 StandoutNobel
Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints
2004 StandoutNobel
Adenovirus-mediated gene delivery and in vitro microinsemination produce offspring from infertile male mice
2002 StandoutNobel
Works of John Abrahamson being referenced
DNA damage, oncogenesis and the p53 tumour-suppressor gene
1994
Prevalence and Penetrance of Germline BRCA1 and BRCA2 Mutations in a Population Series of 649 Women with Ovarian Cancer
2001
Effect of Smoking on Breast Cancer in Carriers of Mutant BRCA1 or BRCA2 Genes
1998
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations
1999
Regulation of p53-Mediated Apoptosis and Cell Cycle Arrest by Steel Factor
1995
No association of the I1307K APC allele with ovarian cancer risk in Ashkenazi Jews.
1998
Are DNA spacers relics of gene amplification events?
1984
p53 regulates a G 2 checkpoint through cyclin B1
1999
Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice.
1994
Proline Dehydrogenase from Escherichia coli K12
1983